Tezcan Gecgil

Tezcan Gecgil

Expertise: ETFs, Options Trading, Technical and Fundamental Analysis

Education: PhD (Business Studies), MSc (Investment Banking & Trading), MBA

Awards & Accomplishments: Completed all 3 levels of the Chartered Market Technician (CMT) qualification

About Tezcan
Tezcan Gecgil, PhD, began contributing to InvestorPlace in 2018. She has worked in investment management in the U.S. and U.K., including a Greenwich, Connecticut-based hedge fund as well as the American Stock Exchange, CFA Institute, and Bloomberg. She has also taught at various U.S. and U.K. universities.

She holds Ph.D. (Business Studies) as well as MSc (Investment Banking & Trading) and MBA degrees from leading U.S. and U.K. universities and has also completed all three levels of the Chartered Market Technician (CMT) examination.

Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. Publicly, she has also contributed to investing.com and the U.K. website of The Motley Fool. She is also part of the investment management writing team at Copylab.

When not navigating the markets, Tezcan delves into the mysteries of history and explores new destinations.

Recent Articles

3 New ProShares ETFs Built for the Trends of the Future

Here are three new ETFs focused on future industries to research further as you decide where to invest your hard-earned wealth.

7 Stocks to Buy That Could Benefit From the Roaring Tesla Rally

The TSLA market capitalization is touching $1.2 trillion. These stocks to buy are well-positioned to benefit from the impressive Tesla rally.

3 Worthy Water Stocks to Tap As Drought Becomes a New Normal

Water has become a multi-billion dollar industry, so these three water stocks should make outstanding additions to any long-term portfolio.

7 Best Tech Stocks to Buy for Q4 Earnings Season

These high-growth tech stocks enjoy solid momentum that could help them outpace the overall market throughout the rest of the year.

Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone

NVAX stock's prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate